Objective To examine the efficacy and safety of the humanized anti–interleukin‐6 receptor
antibody tocilizumab combined with conventional disease‐modifying antirheumatic drugs …

Objective To determine the effects of tocilizumab on rheumatoid arthritis (RA) disease
activity and remission assessment, using measures that do or do not comprise acute‐phase …

Objectives To confirm the effectiveness and safety of the interleukin 6-receptor antagonist
tocilizumab in patients with rheumatoid arthritis (RA) in a setting close to real-life medical …

Objective To establish the safety and efficacy of repeat infusions of tocilizumab (previously
known as MRA), a humanized anti–interleukin‐6 (IL‐6) receptor antibody, alone and in …

We investigated the clinical efficacy and safety of tocilizumab (a humanized anti-IL-6
receptor antibody) monotherapy in active rheumatoid arthritis (RA) patients with an …

Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of
IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through …

Objectives: To evaluate the safety and efficacy of 5-year, long-term tocilizumab monotherapy
for patients with rheumatoid arthritis. Methods: In an open-label, long-term extension trial …

Objective To evaluate efficacy of tocilizumab in US patients with moderate to severe active
rheumatoid arthritis (RA) and inadequate clinical response to disease-modifying …

OBJECTIVES: To compare the patterns of American College of Rheumatology (ACR)
response between tocilizumab and other biologic agents in patients with rheumatoid arthritis …

Objectives: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an
anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to …